VIDEO: ‘Can we cure metastatic NSCLC?’

ByRoy Herbst, MD, PhD

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, highlighted Keynote 24, which was presented at ESMO Virtual Congress 2020.

“I was also the discussant on several abstracts and one of them was Keynote 24: The 5 Year Update,” Herbst, who also serves as ensign professor of medicine and professor of pharmacology, and chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital, explained. “I titled my discussion, ‘Can we cure metastatic non-small cell lung cancer?’ That’s an interesting question.”

References:

Brahmer JR, et al. Abstract LBA51. Presented at: European Society for Medical Oncology Virtual Congress 2020; Sept. 19-21, 2020.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview

Disclosures: Herbst reports receiving research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche and Merck and Company, and serving as a board member for Junshi Pharmaceuticals and as a consultant for AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol‐Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen and WindMIL Therapeutics.

Take Homes in Lung Cancer

Read more

VIDEO: ‘Can we cure metastatic NSCLC?’

References:

Related Content